Personalised therapy for leukemia patients comes a step closer

New York, Feb 16 (IANS) Setting the stage to expand the use of a patient’s genetic make-up to tailor chemotherapy, an international research team has found how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia.

The research focused on treatment-related toxicity associated with a class of medication called thiopurines, which are widely used as anti-cancer and immunosuppressing drugs.

Thiopurines such as mercaptopurine are indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood cancer.

In the study involving 270 children with ALL, the scientists discovered four inherited variations in the NUDT15 gene that alter thiopurine metabolism and leave patients particularly sensitive to the drugs and at risk for treatment-disrupting toxicity.

One in three Japanese patients in this study carried the high-risk variations.

Evidence suggests that the variations are also common in other populations across Asia and those of Hispanic ethnicity, the researchers said.

“This study is key to the development of more effective, personalised ALL therapy because it provides a clear explanation of how variations in the NUDT15 gene change drug metabolism and cause toxicity in patients,” said lead researcher Jun Yang from St. Jude Children’s Research Hospital in Tennessee, US.

In the study published in the journal Nature Genetics, the researchers demonstrated that the NUDT15 enzyme helps to balance thiopurine activity by reducing the supply of the active drug metabolite that triggers cell death.

This check-and-balance mechanism helps to prevent the excessive death of white blood cells that put patients at high risk for infections and other serious complications.

The scientists showed the high-risk NUDT15 variants cause a 74.4 to 100 percent loss of NUDT15 function and a toxic build-up of the drug at standard doses.

“We are planning clinical studies to move these findings from the laboratory to the clinic with the hope to guide individualised therapy in the future,” Yang said.

Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of or any employee thereof. is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here